| Summary of Financial Data for Development of Pharmaceutical Products Segments |
The following tables summarize our financial data for our segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Year Ended June 30, 2026 |
|
|
|
Digital Asset Treasury Strategy |
|
|
Development of Pharmaceutical Products |
|
|
Total Segment Costs |
|
|
Corporate Expenses |
|
|
Consolidated |
|
Operating and other (income) expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee expenses |
|
$ |
811 |
|
|
$ |
45 |
|
|
$ |
856 |
|
|
$ |
1,310 |
|
|
$ |
2,166 |
|
Other segment expenses(1) |
|
|
70 |
|
|
|
16 |
|
|
|
86 |
|
|
|
3,492 |
|
|
|
3,578 |
|
Professional fees |
|
|
718 |
|
|
|
2 |
|
|
|
720 |
|
|
|
1,544 |
|
|
|
2,264 |
|
Legal fees |
|
|
112 |
|
|
|
629 |
|
|
|
741 |
|
|
|
840 |
|
|
|
1,581 |
|
voruciclib |
|
|
— |
|
|
|
59 |
|
|
|
59 |
|
|
|
— |
|
|
|
59 |
|
Asset management fee and advisory fees |
|
|
2,521 |
|
|
|
— |
|
|
|
2,521 |
|
|
|
— |
|
|
|
2,521 |
|
Change in fair value of digital
assets |
|
|
54,408 |
|
|
|
— |
|
|
|
54,408 |
|
|
|
— |
|
|
|
54,408 |
|
Change in fair value of digital
assets receivable, net |
|
|
5,653 |
|
|
|
— |
|
|
|
5,653 |
|
|
|
— |
|
|
|
5,653 |
|
Gain on derivative liabilities, net |
|
|
(813 |
) |
|
|
— |
|
|
|
(813 |
) |
|
|
— |
|
|
|
(813 |
) |
Interest and dividend income(2) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(267 |
) |
|
|
(267 |
) |
Total operating and other
(income) expense |
|
|
63,480 |
|
|
|
751 |
|
|
|
64,231 |
|
|
|
6,919 |
|
|
|
71,150 |
|
Total segment costs loss and
net loss |
|
$ |
(63,480 |
) |
|
$ |
(751 |
) |
|
$ |
(64,231 |
) |
|
$ |
(6,919 |
) |
|
$ |
(71,150 |
) |
______ (1) Includes product development costs associated with zandelisib determined to be immaterial, share-based compensation costs, administrative costs, travel and business taxes. (2) Interest and dividend income are solely attributable to our cash and cash equivalents.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Year Ended June 30, 2025 |
|
|
|
Development of Pharmaceutical Products
and Total Segment Costs |
|
|
Corporate Expenses |
|
|
Consolidated |
|
Operating and other (income) expense |
|
|
|
|
|
|
|
|
|
Employee expenses |
|
$ |
2,602 |
|
|
$ |
6,691 |
|
|
$ |
9,293 |
|
Other segment expenses(1) |
|
|
242 |
|
|
|
2,405 |
|
|
|
2,647 |
|
Professional fees |
|
|
25 |
|
|
|
2,729 |
|
|
|
2,754 |
|
Legal fees |
|
|
602 |
|
|
|
1,121 |
|
|
|
1,723 |
|
voruciclib |
|
|
801 |
|
|
|
— |
|
|
|
801 |
|
ME-344 |
|
|
253 |
|
|
|
— |
|
|
|
253 |
|
Gain on disposition of nonfinancial asset |
|
|
— |
|
|
|
(500 |
) |
|
|
(500 |
) |
Interest and dividend income(2) |
|
|
— |
|
|
|
(1,026 |
) |
|
|
(1,026 |
) |
Total operating and other (income)
expense |
|
|
4,525 |
|
|
|
11,420 |
|
|
|
15,945 |
|
Total segment costs loss and net loss |
|
$ |
(4,525 |
) |
|
$ |
(11,420 |
) |
|
$ |
(15,945 |
) |
______ (1) Includes product development costs associated with zandelisib determined to be immaterial, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes. (2) Interest and dividend income are solely attributable to our cash and cash equivalents.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
|
Digital Asset Treasury Strategy |
|
|
Development of Pharmaceutical Products |
|
|
Total Segment Assets |
|
|
Corporate Assets |
|
|
Consolidated |
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalent |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
5,706 |
|
|
$ |
5,706 |
|
Prepaid expenses and other current assets |
|
|
128 |
|
|
|
31 |
|
|
|
159 |
|
|
|
276 |
|
|
|
435 |
|
Total current assets |
|
|
128 |
|
|
|
31 |
|
|
|
159 |
|
|
|
5,982 |
|
|
|
6,141 |
|
Digital assets |
|
|
27,272 |
|
|
|
— |
|
|
|
27,272 |
|
|
|
— |
|
|
|
27,272 |
|
Digital assets receivable, net |
|
|
7,627 |
|
|
|
— |
|
|
|
7,627 |
|
|
|
— |
|
|
|
7,627 |
|
Investment in SAFE and Token Warrants |
|
|
1,000 |
|
|
|
— |
|
|
|
1,000 |
|
|
|
— |
|
|
|
1,000 |
|
Other long-term assets |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
652 |
|
|
|
652 |
|
Total assets |
|
$ |
36,027 |
|
|
$ |
31 |
|
|
$ |
36,058 |
|
|
$ |
6,634 |
|
|
$ |
42,692 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2025 |
|
|
|
Development of Pharmaceutical Products
and Total Segment Assets |
|
|
Corporate Assets |
|
|
Consolidated |
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalent |
|
$ |
— |
|
|
$ |
18,011 |
|
|
$ |
18,011 |
|
Prepaid expenses and other current assets |
|
|
25 |
|
|
|
249 |
|
|
|
274 |
|
Total current assets |
|
|
25 |
|
|
|
18,260 |
|
|
|
18,285 |
|
Total assets |
|
$ |
25 |
|
|
$ |
18,260 |
|
|
$ |
18,285 |
|
|